Prdm16 Supports Arterial Flow Recovery by Maintaining Endothelial Function.

[Figure: see text].

Exploring polyoxometalates as non-destructive staining agents for contrast-enhanced microfocus computed tomography of biological tissues.

To advance clinical translation of regenerative medicine, there is, amongst others, still need for better insights in tissue development and disease. For this purpose, more precise imaging of the 3D microstructure and spatial interrelationships of the different tissues within organs is crucial. Despite being destructive towards the sample, conventional histology still is the gold standard for structural analysis of biological tissues. It is, however, limited by 2D sections of a 3D object, prohibiting full 3D structural analysis. MicroCT has proven to provide full 3D structural information of mineralized tissues and dense biomaterials. However, the intrinsic low X-ray absorption of soft tissues requires contrast-enhancing staining agents (CESAs). In a previous study, we showed that hafnium-substituted Wells-Dawson polyoxometalate (Hf-WD POM) allows simultaneous contrast-enhanced microCT (CE-CT) visualization of bone and its marrow vascularization and adiposity. In this study, other POM species have been examined for their potential as soft tissue CESAs. Four Wells-Dawson POMs, differing in structure and overall charge, were used to stain murine long bones and kidneys. Their staining potential and diffusion rate were compared to those of Hf-WD POM and phosphotungstic acid (PTA), a frequently used but destructive CESA. Monolacunary Wells-Dawson POM (Mono-WD POM) showed similar soft tissue enhancement as Hf-WD POM and PTA. Moreover, Mono-WD POM is less destructive, shows a better diffusion than PTA, and its synthesis requires less time and cost than Hf-WD POM. Finally, the solubility of Mono-WD POM was improved by addition of lithium chloride (LiCl) to the staining solution, enhancing further the soft tissue contrast. STATEMENT OF SIGNIFICANCE: To advance clinical translation of regenerative medicine, there is, amongst others, still need for better insights in tissue development and disease. For this purpose, more precise imaging of the 3D microstructure and spatial interrelationships of the different tissues within organs is crucial. Current standard structural analysis techniques (e.g. 2D histomorphometry), however, do not allow full 3D assessment. Contrast-enhanced X-ray computed tomography has emerged as a powerful 3D structural characterization tool of soft biological tissues. In this study, from a library of Wells Dawson polyoxometalates (WD POMs), we identified monolacunary WD POM together with lithium chloride, dissolved in phosphate buffered saline, as the most suitable contrast-enhancing staining agent solution for different biological tissues without tissue shrinkage.

Deciphering the combined effect of bone morphogenetic protein 6 and calcium phosphate on bone formation capacity of periosteum derived cells-based tissue engineering constructs.

Cell based combination products with growth factors on optimal carriers represent a promising tissue engineering strategy to treat large bone defects. In this concept, bone morphogenetic protein (BMP) and calcium phosphate (CaP)-based scaffolds can act as potent components of the constructs to steer stem cell specification, differentiation and initiate subsequent in vivo bone formation. However, limited insight into BMP dosage and the cross-talk between BMP and CaP materials, hampers the optimization of in vivo bone formation and subsequent clinical translation. Herein, we combined human periosteum derived progenitor cells with different doses of BMP6 and with three types of clinical grade CaP-scaffolds (ChronOs®, ReproBone™, & CopiOs®). Comprehensive cellular and molecular analysis was performed based on in vitro cell metabolic activity and signaling pathway activation, as well as in vivo ectopic bone forming capacity after 2 weeks and 5 weeks in nude mice. Our data showed that cells seeded on CaP scaffolds with an intermediate Ca2+ release rate combined with low or medium dosage of BMP6 demonstrated a robust new bone formation after 5 weeks, which was contributed by both donor and host cells. This phenomenon might be due to the delicate balance between Ca2+ and BMP pathways, allowing an appropriate activation of the canonical BMP signaling pathway that is required for in vivo bone formation. For high BMP6 dosage, we found that the BMP6 dosage overrides the effect of the Ca2+ release rate and this appeared to be a dominant factor for ectopic bone formation. Taken together, this study illustrates the importance of matching BMP dosage and CaP properties to allow an appropriate activation of canonical BMP signaling that is crucial for in vivo bone formation. It also provides insightful knowledge with regard to clinical translation of cell-based constructs for bone regeneration. STATEMENT OF SIGNIFICANCE: The combination of bone morphogenetic proteins (BMP) and calcium phosphate (CaP)-based biomaterials with mesenchymal stromal cells represents a promising therapeutic strategy to treat large bone defects, an unmet medical need. However, there is limited insight into the optimization of these combination products, which hampers subsequent successful clinical translation. Our data reveal a delicate balance between Ca2+ and BMP pathways, allowing an appropriate activation of canonical BMP signaling required for in vivo bone formation. Our findings illustrate the importance of matching BMP dosage and CaP properties in the development of cell-based constructs for bone regeneration.